Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1,584,707
-
Number of holders
-
14
-
Total 13F shares, excl. options
-
202,365
-
Shares change
-
-26,944
-
Total reported value, excl. options
-
$200,198
-
Value change
-
-$40,809
-
Number of buys
-
4
-
Number of sells
-
5
-
Price
-
$0.9900
Institutional Holders of Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) as of Q3 2024
As of 30 Sep 2024 Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) had 14 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 202,365 shares of stock of the company.
Largest 10 holders included ARMISTICE CAPITAL, LLC, Point72 Asset Management, L.P., ACADIAN ASSET MANAGEMENT LLC, UBS Group AG, GEODE CAPITAL MANAGEMENT, LLC, Tower Research Capital LLC (TRC), McIlrath & Eck, LLC, Activest Wealth Management, OSAIC HOLDINGS, INC., and MORGAN STANLEY.
This table shows 14 institutional shareholders of the security as of 30 Sep 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.